RxDoctor Payments Data

Paula Hayes

Family · Ballston Lake, NYNPI 1013356500

Payments from drug & device makers

$3,232in general payments, 2019–2025

Across 113 payments — averaging $28.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$742
  • Novo Nordisk$442
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$254
  • Boston Scientific$219
  • Sanofi-aventis U.S. LLC$183
  • Urovant Sciences Inc$125
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,232100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,232 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$14,385
Medicare patients
71
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$31,684
EliquisApixaban14$8,110
SynthroidLevothyroxine Sodium23$2,601
Albuterol Sulfate HfaAlbuterol Sulfate20$561
Metoprolol Succinate29$501
Omeprazole45$458
Levothyroxine Sodium39$454
Atorvastatin Calcium36$360
Fluticasone Propionate11$303
Gabapentin20$223
Lisinopril29$214
Cephalexin22$189
Escitalopram Oxalate23$171
Triamcinolone Acetonide19$153
Losartan Potassium19$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$442$31,68414 claims
PfizerEliquis$71$8,11014 claims
AbbVieSynthroid$742$2,60123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Ballston Lake

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →